METCELA
Metcela is a clinical-stage biotech startup providing patients with an innovative and alternative treatment option for heart disease. The company's lead asset, MTC001 is a cell therapy based on VCAM-1-positive Cardiac Fibroblast (VCF) that re-established a favorable microenvironment and repaired damaged heart tissues in preclinical studies. Metcela's therapy uses a specific fibroblast cell that is obtained from the patient's heart and instead of replacing them, it repairs the damage by enhancing the cells' ability to heal, providing patients with an effective and reasonably-priced cure for heart failure. It was founded on March 9, 2016, and is headquartered in Kawasaki, Japan.
METCELA
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2016-03-09
Address:
Kawasaki, Kanagawa, Japan
Country:
Japan
Website Url:
http://www.metcela.com
Total Employee:
11+
Status:
Active
Total Funding:
35.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Lucy Therapeutics
Lucy Therapeutics is a biotech company providing effective treatments for neurological diseases start with the mitochondria.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
CEJ Fund
CEJ Fund investment in Series C - Metcela
Cyberdyne
Cyberdyne investment in Series C - Metcela
Reazon Holdings
Reazon Holdings investment in Series C - Metcela
Japan Lifeline
Japan Lifeline investment in Series C - Metcela
Sony Innovation Fund
Sony Innovation Fund investment in Series C - Metcela
Tsukuba Exceed Fund
Tsukuba Exceed Fund investment in Series B - Metcela
MAKOTO Capital
MAKOTO Capital investment in Series B - Metcela
Alfresa Holdings
Alfresa Holdings investment in Series B - Metcela
Sony Innovation Fund
Sony Innovation Fund investment in Series B - Metcela
Eight Roads Ventures
Eight Roads Ventures investment in Series B - Metcela
Official Site Inspections
http://www.metcela.com Semrush global rank: 2.79 M Semrush visits lastest month: 5.82 K
- Host name: users306.vip.heteml.jp
- IP address: 157.7.44.181
- Location: Tokyo Japan
- Latitude: 35.6882
- Longitude: 139.7532
- Timezone: Asia/Tokyo
- Postal: 102-0082
More informations about "Metcela"
Metcela | Unleash the Cell Potential
Metcela eligible to receive up to $7 Million (1 Billion JPY) AMED Grant for Promoting the Development of Regenerative Medicine Product Using Cardiac Stem CellsSee details»
CORPORATE - metcela.com
Jul 1, 2024 · Metcela Inc. Founded: March 9, 2016. Research and development of stem cell and fibroblast-based therapies for cardiac diseases.See details»
Metcela - Crunchbase Company Profile & Funding
Metcela is a clinical-stage biotech startup providing patients with an innovative and alternative treatment option for heart disease. The company's lead asset, MTC001 is a cell therapy based on VCAM-1-positive Cardiac Fibroblast (VCF) …See details»
株式会社メトセラ | 細胞の力を生きる力に
わたしたちは、サイエンスでその可能性を切りひらき、世界中の患者さんの生きる力へとつなげていきます。See details»
The Forum for Innovative Regenerative Medicine (FIRM) Ver.1.0 …
Metcela believes that delivery method for cell-based therapy for the heart is as important as the cells itself. Collaborating with a Japanese catheter company and cardiologists, we specifically …See details»
Metcela Inc. - J-Startup
Metcela Inc. is a pre-clinical stage biotech startup in Japan, developing a cell therapy for heart failure. Though the number of heart failure patients is increasing due to the increasing …See details»
Metcela Inc. | LinkedIn
Our goal is to develop and commercialize an effective and reasonably-priced therapy for heart failure using a specific fibroblast cells we call “VCF”, that we obtain from the patient’s own heart.See details»
Metcela - Treating chronic organ diseases using a novel fibroblast ...
Jan 2, 2024 · Kenichi Nogami is the co-founder and CEO of Metcela, a clinical-stage biotechnology startup pioneering the research and development of fibroblast and stem cell …See details»
METCELA INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for METCELA INC. of KAWASAKI, KANAGAWA. Get the latest business insights from Dun & Bradstreet.See details»
Metcela Company Profile 2024: Valuation, Funding & Investors
Developer of biological therapy intended to provide treatment for heart disease. The company's therapy uses a specific fibroblast cell obtained from the patient's heart and instead of replacing …See details»
【News】Capital and business alliance with Metcela Inc
Metcela is a clinical development stage startup that aims to provide new fibroblast and stem cell-based therapies for chronic diseases that are inadequately responding to existing treatments. …See details»
Metcela to Strengthen Clinical Pipeline Development, New …
Dec 6, 2023 · Through the merger with Japan Regenerative Medicine, we have established an organizational structure that enables us to implement the entire process from discovery to …See details»
Metcela - Company Profile - Tracxn
Nov 18, 2024 · Metcela - Developer of regenerative biological product for the treatment of heart failure. Raised a total funding of $36.7M over 5 rounds from 13 investors. Founded by Kenichi …See details»
Metcela - Contacts, Employees, Board Members, Advisors & Alumni
Metcela is a clinical-stage biotech startup providing patients with an alternative treatment option for heart disease.See details»
株式会社メトセラ - J-Startup
Https://www.metcela.com メトセラは2016年3月に創業した、心疾患向けの細胞医薬品を開発するベンチャー企業です。 心不全は高齢化の進展や生活習慣病によって患者数の増加が見込ま …See details»
Metcela Eligible to Receive up to $7 Million (1 Billion JPY) AMED …
Metcela Inc., established in 2016, is a clinical-stage biotechnology startup pioneering the research and development of fibroblast and stem cell-based therapy for chronic diseases that currently …See details»
Metcela Secures $12.7 Million Series B Financing to Initiate
Jan 4, 2021 · Metcela Inc., a clinical-stage biotech startup specializing in fibroblast-based cell therapy, announced the closing of its $12.7 million (1.3 billion yen) Series B round, led by The …See details»
Metcela Company Profile - Office Locations, Competitors ... - Craft
Metcela is a biotech company engaged in research and development of fibroblast-based therapies for cardiac diseases. It develops a therapy for heart failure using specific fibroblast cells …See details»
Metcela Appoints New Board Members and
Metcela Inc., established in 2016, is a clinical-stage biotechnology startup pioneering the research and development of fibroblast and stem cell-based therapy for chronic diseases that currently …See details»
Meta Developers - Oculus VR
Manage your organization. Create your organization. Add financial settings. Get financial reports. Verify your org. Manage multiple orgs. Manage test users. Business models and strategy. …See details»